- The agreement includes the exclusive commercialization and distribution of Monofer® in selected countries in Latin America.
- This alliance strengthens SteinCares’ leadership as a strategic partner for global companies committed to the well-being of patients in the region.
San Jose, Costa Rica, September 2023. SteinCares, one of Latin America’s leading specialty healthcare companies, announces its exclusive licensing agreement with Pharmacosmos to commercialize and distribute Monofer®, an innovative intravenous iron replacement therapy for patients with a deficiency of this mineral.
Through this strategic alliance, SteinCares strengthens its product portfolio in hematology and nephrology with an innovative and high-quality treatment for Latin American patients with iron deficiency anemia.
“We are very excited about this partnership with Pharmacosmos, a leading international company that specializes in iron treatments. Monofer® will provide patients in the region with an innovative and cost-effective treatment option for iron deficiency anemia. In addition, this agreement reinforces our position as a strategic partner for global pharmaceutical companies that bet on Latin America,” stated Sebastian Katz, Chief Strategy Officer at SteinCares.
Claes C Strom, Chief Commercial Officer at Pharmacosmos, also commented on his enthusiasm for the signing of this deal. “This agreement represents an important milestone as Latin America is a market with great potential. We are confident that SteinCares’ strong track record in hematology and nephrology, combined with our company’s expertise in iron treatments, will provide an excellent platform for Monofer® in the region. We have no doubts this product will serve unmet needs for iron-deficient patients.”
Monofer® is an innovative iron-carbohydrate complex for high-dose intravenous administration, for the treatment of iron deficiency and represents a more convenient therapeutic option. It is already marketed in Asia, Europe, and North America. Its entry into Latin America represents a new treatment alternative for patients in a region where a high percentage of the population may suffer from anemia, which tends to be under-diagnosed.
About Pharmacosmos Group
Pharmacosmos Group, headquartered in Holbaek, Denmark, and founded in 1965, is a highly specialised company focused on carbohydrate chemistry and a global leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia. With companies in the UK, Nordics, Germany, the USA, and China, as well as through partners, Pharmacosmos markets its products around the world. With a strong and ongoing commitment to R&D, Pharmacosmos is able to leverage a unique carbohydrate production platform along with deep expertise in the synthesis of iron-carbohydrate complexes. The Pharmacosmos Group has more than 500 employees.
For more information, please visit https://www.pharmacosmos.com/
About Stein Cares
SteinCares is a leader in commercializing and distributing specialty healthcare products in Latin America, including innovative pharmaceuticals, biosimilars and complex generics. With over 40 years of progressive healthcare experience and presence in more than 30 countries in Latin America and the Caribbean, SteinCares serves as a bridge between the world’s pharmaceutical companies and the region’s healthcare providers.
The company is highly committed to creating healthcare opportunities that positively impact the lives of patients and their families in Latin America, as it has the vision to giving more access to innovative and cost-effective healthcare to patients in the region.
For more information, please contact:
Marketing and Corporate Communications Manager| SteinCares
email@example.com, +54 911 6367 1612
Christian Lundquist Madsen
Head of Global Marketing | Pharmacosmos
firstname.lastname@example.org, +45 5948 5959